Page last updated: 2024-10-26

doxazosin and Sclerosis

doxazosin has been researched along with Sclerosis in 1 studies

Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.

Sclerosis: A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve.

Research Excerpts

ExcerptRelevanceReference
"To assess the renal benefits of combined angiotensin-converting enzyme inhibition and alpha(1)-adrenergic antagonism, we studied the antihypertensive and renoprotective effects of temocapril (TMP) alone and in combination with doxazosin (DOX) in spontaneously hypertensive rats (SHR)/Izumo rats with renal ablation."1.32Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation. ( Abe, K; Ito, O; Kanazawa, M; Kohzuki, M; Kurosawa, H; Minami, N; Saito, T; Yasujima, M, 2004)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kanazawa, M1
Kohzuki, M1
Kurosawa, H1
Minami, N1
Ito, O1
Saito, T1
Yasujima, M1
Abe, K1

Other Studies

1 other study available for doxazosin and Sclerosis

ArticleYear
Renoprotective effect of angiotensin-converting enzyme inhibitor combined with alpha1-adrenergic antagonist in spontaneously hypertensive rats with renal ablation.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2004, Volume: 27, Issue:7

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Albuminuria; Angiotensin-Conv

2004